AbCellera Biologics Inc.
ABCL · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $862,380 | $1,651,141 | $2,887,623 | $3,943,422 |
| - Cash | $156,325 | $133,320 | $386,535 | $476,142 |
| + Debt | $65,364 | $77,380 | $82,258 | $40,065 |
| Enterprise Value | $771,419 | $1,595,201 | $2,583,346 | $3,507,345 |
| Revenue | $28,833 | $38,025 | $485,424 | $375,203 |
| % Growth | -24.2% | -92.2% | 29.4% | – |
| Gross Profit | $28,833 | $38,025 | $418,988 | $329,687 |
| % Margin | 100% | 100% | 86.3% | 87.9% |
| EBITDA | -$204,148 | -$192,158 | $260,167 | $239,149 |
| % Margin | -708% | -505.3% | 53.6% | 63.7% |
| Net Income | -$162,857 | -$146,398 | $158,519 | $153,464 |
| % Margin | -564.8% | -385% | 32.7% | 40.9% |
| EPS Diluted | -0.55 | -0.51 | 0.5 | 0.48 |
| % Growth | -7.8% | -202% | 4.2% | – |
| Operating Cash Flow | -$108,556 | -$43,877 | $277,360 | $244,584 |
| Capital Expenditures | -$78,396 | -$77,507 | -$72,660 | -$58,452 |
| Free Cash Flow | -$186,952 | -$121,384 | $204,700 | $186,132 |